Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG)
Author(s) -
Laura M. Willemsen,
Paul W.A. Janssen,
Joyce Peper,
Mohamed A. Soliman Hamad,
Albert H.M. van Straten,
Patrick Klein,
C. M. Hackeng,
Uday Sonker,
Margreet W.A. Bekker,
Clemens von Birgelen,
Marc A. Brouwer,
Pim van der Harst,
Eline A. Vlot,
Vera H.M. Deneer,
Dean R.P.P. Chan Pin Yin,
Marieke E. Gimbel,
Kasper F. Beukema,
Edgar J. Daeter,
Johannes C. Kelder,
Jan G.P. Tijssen,
Benno J. Rensing,
Hendrik W. van Es,
Martin J. Swaans,
Jurriën M. ten Berg
Publication year - 2020
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.120.050749
Subject(s) - medicine , ticagrelor , cardiology , aspirin , myocardial infarction , placebo , artery , coronary artery bypass surgery , revascularization , surgery , acute coronary syndrome , alternative medicine , pathology
Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after coronary artery bypass graft surgery (CABG) despite aspirin use. The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom